RT Journal Article
T1 European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.
A1 Garbe, Claus
A1 Amaral, Teresa
A1 Peris, Ketty
A1 Hauschild, Axel
A1 Arenberger, Petr
A1 Basset-Seguin, Nicole
A1 Bastholt, Lars
A1 Bataille, Veronique
A1 Del Marmol, Veronique
A1 Dréno, Brigitte
A1 Fargnoli, Maria C
A1 Forsea, Ana-Maria
A1 Grob, Jean-Jacques
A1 Hoeller, Christoph
A1 Kaufmann, Roland
A1 Kelleners-Smeets, Nicole
A1 Lallas, Aimilios
A1 Lebbé, Celeste
A1 Lytvynenko, Bodhan
A1 Malvehy, Josep
A1 Moreno-Ramirez, David
A1 Nathan, Paul
A1 Pellacani, Giovanni
A1 Saiag, Philippe
A1 Stratigos, Alexander J
A1 Van Akkooi, Alexander C J
A1 Vieira, Ricardo
A1 Zalaudek, Iris
A1 Lorigan, Paul
A1 European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)
K1 Adjuvant treatment
K1 Cutaneous melanoma
K1 Excisional margins
K1 Interferon-α
K1 Metastasectomy
K1 Sentinel lymph node dissection
K1 Systemic treatment
K1 Tumor thickness
AB A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on the systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumor thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("tumor board"). Adjuvant therapies can be proposed in stage III/completely resected stage IV patients and are primarily anti-PD-1, independent of mutational status, or alternatively dabrafenib plus trametinib for BRAF mutant patients. In distant metastases (stage IV), either resected or not, systemic treatment is always indicated. For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600  E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600  E/K mutation, this therapy shall be offered as second-line therapy. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.
YR 2022
FD 2022-05-24
LK http://hdl.handle.net/10668/22176
UL http://hdl.handle.net/10668/22176
LA en
DS RISalud
RD Apr 5, 2025